

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute, and is not intended to be, an invitation or offer to acquire, purchase or subscribe for, or offer to sell or a solicitation of any offer to buy securities in Hong Kong, the People's Republic of China or elsewhere.*

## **PW MEDTECH GROUP LIMITED**

### **普华和顺集团公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1358)**

### **PROGRESS ON PROPOSED SPIN-OFF OF SICHUAN RUIJIAN MEDICAL**

Reference is made to the announcements of the Company dated May 20, 2024 and July 2, 2024 in relation to the Proposed Spin-off (the “**Announcements**”). Unless otherwise defined, the terms used herein shall have the same meaning as those defined in the Announcements. The Board hereby provides the latest update on the Proposed Spin-off to its Shareholders.

On September 30, 2024, Sichuan Ruijian Medical received the letter on “Approving the public transfer and quotation of shares of Sichuan Ruijian Medical on the NEEQS” (the “**Letter**”) issued by the NEEQ Co., Ltd., approving the NEEQS Quotation. The Letter has been disclosed on the designated disclosure platform of the NEEQ ([www.neeq.com.cn](http://www.neeq.com.cn)) on September 30, 2024 for investors’ reference.

After the NEEQS Quotation, Sichuan Ruijian Medical will remain as a non-wholly owned subsidiary of the Company. Sichuan Ruijian Medical will go through the formalities for the NEEQS Quotation in accordance with relevant regulations. It is expected that the NEEQS Quotation will be completed around October 31, 2024. The Company will publish announcement to further update its Shareholders of the progress of the NEEQS Quotation.

As part of the Proposed Spin-off, Sichuan Ruijian Medical, subject to the then market conditions and its strategic development needs, may proceed the Subsequent Listing after the NEEQS Quotation. It is intended that Sichuan Ruijian Medical will remain as a subsidiary of the Company upon completion of the Subsequent Listing subject to the Company and its auditor’s assessment under HKFRS. The Subsequent Listing, if materialized, may constitute a deemed disposal and a notifiable transaction of the Company under Chapter 14 of the Listing Rules. The Company will comply with the relevant announcement and/or Shareholders’ approval requirements (if applicable) where appropriate. Further announcement(s) will be made by the Company in accordance with the Listing Rules as and when appropriate.

**Shareholders and potential investors should note that the Proposed Spin-off is subject to, among other things, the prevailing market conditions and approvals from relevant authorities, including the NEEQS, the CSRC and Beijing Stock Exchange. Accordingly, Shareholders and potential investors should be aware that the Company does not guarantee that the Proposed Spin-off will materialize, nor the timing thereof. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**PW Medtech Group Limited**  
普华和顺集团公司  
**Yue'e Zhang**  
*Chairman & Chief Executive Officer*

Hong Kong, October 2, 2024

*As at the date of this announcement, the Board comprises one executive director, namely, Ms. Yue'e Zhang; two non-executive directors, namely Mr. Jiang Liwei and Mr. Lin Junshan; and three independent non-executive directors, namely, Mr. Wang Xiaogang, Mr. Chen Geng and Ms. Wang Fengli.*